ReviewBiomedicines2017
A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia.
Review in Biomedicines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 62 citations in OpenAlex.
- Trip killers: Addressing a critical knowledge gap in psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026Review
- Advancing chronic low back pain management: Insights from amitriptyline and duloxetine comparison.World journal of methodology · 2026Article
- Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Review
- A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System.Biomedicines · 2025Review
- Repurposing Neurological Drugs Against Dengue Virus Infection.Journal of tropical medicine · 2025Review
- Prospects of Electrocorticography in Neuropharmacological Studies in Small Laboratory Animals.Brain sciences · 2024Review
- Overview: Chronic Pain and Cannabis-Based Medicines.Pharmacopsychiatry · 2024Review
- An Overview of Degradation Strategies for Amitriptyline.International journal of molecular sciences · 2024Review
- Assessing Dose- and Sex-Dependent Antinociceptive Effects of Cannabidiol and Amitriptyline, Alone and in Combination, and Exploring Mechanism of Action Involving Serotonin 1A Receptors.The Journal of pharmacology and experimental therapeutics · 2024Article
- Amitriptyline inhibits bronchoconstriction and directly promotes dilatation of the airways.Respiratory research · 2023Article
- Global Research Trends and Hotspots Analysis of the Scientific Production of Amitriptyline: A Bibliometric Approach.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Syntheses, crystal structures and Hirshfeld surface analyses of four mol-ecular salts of amitriptynol.Acta crystallographica. Section E, Crystallographic communications · 2023Article
- Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A Link Between Inflammatory Mechanisms and Fibromyalgia.Advances in experimental medicine and biology · 2023Article
- Amitriptyline-Based Biodegradable PEG-PLGA Self-Assembled Nanoparticles Accelerate Cutaneous Wound Healing in Diabetic Rats.Pharmaceutics · 2022Article
- Novel Presentation of Cardiotoxicity and Other Complications in Tricyclic Antidepressant Poisoning.Cureus · 2021Article
- Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review.Pharmaceutics · 2021Review
- Tricyclic Antidepressant Structure-Related Alterations in Calcium-Dependent Inhibition and Open-Channel Block of NMDA Receptors.Frontiers in pharmacology · 2021Article
- Examination and characterisation of the effect of amitriptyline therapy for chronic neuropathic pain on neuropeptide and proteomic constituents of human cerebrospinal fluid.Brain, behavior, & immunity - health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia is a complex chronic condition characterized by pain, physical fatigue, sleep disorder and cognitive impairment. Evidence-based guidelines recommend antidepressants as treatments of fibromyalgia where tricyclics are often considered to have the greatest efficacy, with amitriptyline often being a first-line treatment. Amitriptyline evokes a preferential reduction in pain and fatigue of fibromyalgia, and in the Fibromyalgia Impact Questionnaire (FIQ) score, which is a quality of life assessment. The multimodal profile of the mechanisms of action of amitriptyline include monoamine reuptake inhibition, receptor modulation and ion channel modulation. Several of the actions of amitriptyline on multiple nociceptive and sensory processes at central and peripheral locations have the potential to act cumulatively to suppress the characteristic symptoms of fibromyalgia. Greater understanding of the role of these mechanisms of action of amitriptyline could provide further clues to the pathophysiology of fibromyalgia and to a preferable pharmacological profile for future drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.